retatrutide triple agonist glp-1 gip glucagon phase 2 results Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports Retatrutide for weight loss: Study

Key Takeaways Folks who take one of the popular GLP-1 weight-loss meds might end up with a cancelled endoscopy or colonoscopy New research suggests the drugs slow the transit of food through the stomach and bowel, leading to imperfect bowel prep before the procedures More research needs to be done to determine if recommendations around bowel prep need to be changed TUESDAY, Oct

Endo Passed Overview GLOW is a three-component peptide blend containing BPC-157, TB-500, and GHK-Cu

doi: 10.1038/ajg.2010.218 156 UzzanM.MartinJ

Hendershot et al randomized 48 participants with alcohol use disorder to semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1.0 mg for 1 week) or placebo for 9 weeks (348)